临床肿瘤学杂志

• 论著 • 上一篇    下一篇

肺腺癌HOXA10基因启动子甲基化的改变及其临床意义

原薇薇1,江恒2,谭艳1,程朋1,苏晓妹1,李东1,罗巧丽1,张涛1   

  1. 1 610083 成都 解放军成都军区总医院肿瘤中心 2 610021 解放军第452 医院肿瘤科
  • 收稿日期:2015-11-12 修回日期:2016-01-12 出版日期:2016-04-30 发布日期:2016-04-30
  • 通讯作者: 张涛

The promoter hypomethylation of HOXA10 gene in lung adenocarcinoma and its clinical significance

YUAN Weiwei,JIANG Heng,TAN Yan,CHENG Peng,SU Xiaomei,LI Dong,LUO Qiaoli,ZHANG Tao   

  1. Center of Oncology,PLA General Hospital of Chengdu Military Command,Chengdu 610083,China
  • Received:2015-11-12 Revised:2016-01-12 Online:2016-04-30 Published:2016-04-30
  • Contact: ZHANG Tao

摘要: 目的 探讨肺腺癌HOXA10基因启动子区甲基化改变情况及其与临床病理特征和预后的关系。方法 采用甲基化特异性聚合酶链反应(MSP)法检测30例肺腺癌标本及其配对癌旁组织标本中HOXA10基因启动子甲基化状态,并分析HOXA10基因甲基化状态与临床病理特征和预后的关系。结果 MSP法检出17例(56.7%)肺腺癌组织HOXA10基因启动子区发生低甲基化改变,其中4例为完全去甲基化改变;而癌旁组织仅有6例(20.0%)HOXA10基因启动子区发生低甲基化改变(P<0.05)。HOXA10低甲基化与肿瘤大小、临床分期及淋巴转移有关(P<0.05),而与性别、年龄、肿瘤分化程度无关(P>0.05)。生存分析显示,HOXA10基因低甲基化患者的中位无病生存期为27.0个月,明显低于HOXA10基因甲基化患者的46.0个月(P=0.002)。结论 肺腺癌HOXA10基因启动子区低甲基化为频发事件,提示与患者的不良预后有关,可作为判断肺腺癌预后的指标。

Abstract: Objective To investigate the methylation status of promoter of HOXA10 gene in lung adenocarcinoma and its correlation with clinicopathologic characteristics and prognosis. Methods Methylation-specific polymerase chain reaction(MSP)was used to examine the promoter hypomethylation in 30 lung adenocarcinoma samples and their corresponding lung normal tissues. The relationship between the hypomethylation status and clinicopathologic features, prognosis was analyzed. Results MSP test indicated that 17 cases(56.7%)of 30 lung adenocarcinoma samples showed hypomethylation of HOXA10 promoter,and 4 cases were even complete demethylation. But only 6 cases(20.0%)of 30 corresponding lung normal tissues showed promoter hypomethylation(P<0.05). Analysis revealed that the frequency of hypomethylation was correlated with size of tumor,clinical stage and lymph node metastasis(P<0. 05),but not with age,gender and tumor differentiation(P>0.05). Statistical analysis showed that the median diseasefree survival of patients with HOXA10 hypomethylation was 27.0 months,which was significantly lower than 46.0 months of those with HOXA10 methylation(P=0.002). Conclusion HOXA10 gene promoter hypomethylation is a frequent epigenetic event in lung adenocarcinoma,which indicates poor prognosis of patients. It may be a biological marker to predict the prognosis for lung adenocarcinoma.

No related articles found!
Viewed
Full text


Abstract

Cited

  Shared   
  Discussed   
No Suggested Reading articles found!